Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117754 · ClinicalTrials.gov registry record · Phase 3
Terbinafine Compared to Griseofulvin in Children With Tinea Capitis
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 720
- Enrollment target
NCT00117754 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 720 participants.
The verdict
NCT00117754, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 720 participants
- Enrollment target
Study Summary
Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis.
Interventions
- DRUG Terbinafine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00117754
The ClinicalTrials.gov registry entry for NCT00117754 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Terbinafine hydrochloride is the first listed.
NCT00117754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00117754 about?
NCT00117754 is a clinical study titled "Terbinafine Compared to Griseofulvin in Children With Tinea Capitis". Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by ...
What is the current status of trial NCT00117754?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 720 participants. The study started on 2004-07. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00117754?
The interventions under investigation include: Terbinafine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00117754?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.